Guangdong Walvax Pharmaceuticals Technology Co., Ltd. announced that it has received CNY 60 million in equity round of funding on July 27, 2021. The transaction included participation from existing investor Walvax Biotechnology Co., Ltd. to retain its 100% stake. Upon closing, the registered capital of the company will increase from CNY 50 million to CNY 110 million. The transaction has been approved in 21st meeting of the 2021 President’s Office. The company completed the industrial and commercial change registration procedures and has obtained the Business License issued by the administrative department for industry and commerce.